The reported decline reflected the mid-2025 formation of Otsuka ICU Medical LLC and the resulting deconsolidation of the IV Solutions business from ICU Medical’s income statement. He said ICU Medical does not feel compelled to pursue a value-destructive transaction solely to achieve a modest increase in growth. ICU Medical spent $11 million on quality-system and product-related remediation activities, $11 million on restructuring and integration, and $19 million on capital expenditures. ICU Medical also highlighted products including LifeShield, Plum Duo and Solo, which Jain said are being well received. About ICU Medical (NASDAQ:ICUI)ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide.